Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review

Thrombosis Research

Volumn 136, Issue 1, 2015, Pages 7-12

  Adcock, D M ^a   Gosselin, R ^b  

^a LABORATORY CORPORATION OF AMERICA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Direct thrombin inhibitor; Direct Xa inhibitor; DOAC; Laboratory assays; Oral anticoagulant

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; ANTITHROMBIN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TEST; CALIBRATION; CLINICAL LABORATORY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SCREENING; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; ANIMAL; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; DRUG MONITORING; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DABIGATRAN; DRUG MONITORING; FACTOR XA INHIBITORS; HUMANS;

EID: 84931567140     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.05.001     Document Type: Review

References (52)

1. G.D. Barnes, W. Ageno, J. Ansell, and Kaatz Recommendation on the nomenclature for oral anticoagulants. On behalf of the Control of Anticoagulation Subcommittee of the SSC of the ISTH J Thromb Haemost 2015 10.1111/JTH.12969 [epub ahead of print]
2. http:/www.cdc.gov/ncbddd/dvt/data/html
3. G.V. Naccarelli, H. Varker, J. Lin, and K.L. Schulman Increasing prevalence of atrial fibrillation and flutter in the United States Am J Cardiol 104 2009 1534 1539
4. C. Zhan, R. Kaczmarek, N. Loyo-Berrios, J. Sangl, and R.A. Bright Incidence and short-term outcomes of primary and revision hip replacement in the United States J Bone Joint Surg Am 89 2007 526 533
5. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, D. Phil, and J. Eikelboom Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
6. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation N Engl J Med 365 10 2011 883 891
7. B. Granger, J.H. Alexander, J.V.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus Warfarin in Patients with Atrial Fibrillation N Engl J Med 365 11 2011 981 992
8. H. Bounemeaux, and A.J. Camm Edoxaban: An update on the new oral direct factor Xa inhibitor Drugs 74 2014 1209 1231
9. C.H. Yeh, P.L. Gross, and J. Weitz Evolving use of new oral anticoagulants for the treatment of venous thromboembolism Blood 124 2014 1020 1028
10. N. van Es, M. Coppen, S. Schulman, S. Middeldorp, and H.R. Buller Direct oral anticoagulants compared with vitamin K antagonists for acute thromboembolism: evidence from phase 3 trials Blood 124 2014 1968 1975
11. H. Bounameaux, and G. Reber New oral anticoagulants: a need for laboratory monitoring. Against J Thromb Haemost 8 2010 627 630
12. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
13. W. Mueck, L.C. Borris, O.E. Dahl, S. Haas, M.V. Huisman, and A.K. Kakkar Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Haemost 100 2008 453 461
14. R.C. Becker, J.H. Alexander, L.K. Newby, H. Yang, Y. Barrett, and P. Mohan Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome Thromb Haemost 104 2010 976 983
15. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Masumoto, T. Oguma, and M. Kojima Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
16. G.Y.H. Lip, and G. Agnelli Edoxaban: a focused review of its clinical pharmacology Eur Heart J 35 2014 1844 1855
17. K. Saraf, P. Morris, P. Garg, P. Sheridan, and R. Storey Non-vitamin K oral anticoagulants NOACS: clinical evidence and therapeutic considerations Postgrad Med J 90 2014 520 528
18. L. Masotti, and M. Campanini Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics Ital J Med 7 2013 1 7
19. G. Lippi, and E. Favaloro Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACS): is there consensus? Clin Chem Lab Med 2014 10.1515/cclm-2014-0767
20. M.M. Samama, and C. Guinet Laboratory assessment of new anticoagulants Clin Chem Lab Med 49 2011 761 772
21. Tl Lindahl, F. Baghaei, I.F. Blixter, K.M. Gustafsson, L. Stigendal, and M. Sten-Linder Effects of the oral, direct thrombin inhibitor dabigatran on five common assays Thromb Haemost 105 2011 371 378
22. J. Harenberg, S. Erdle, S. Marx, M. Math, and R. Kramer Determination of rivaroxaban in human plasma samples Semin Thromb Hemost 38 2012 178 184
23. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 104 6 2010 1263 1271
24. M. Van Blerk, E. Bailleul, B. Chatelain, A. DeMulder, and K. Devrees Influence of dabigatran and rivaroxaban on routine coagulation assays Thromb Haemost 113 2015 154 164
25. S. Haas Facts and artifacts of coagulation assays for factor Xa inhibitors Thromb Haemost 103 2010 686 688
26. J. Douxfils, C. Chatelain, B. Chatelain, J.M. Dogné, and F. Mullier Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide Thromb Haemost 110 2013 283 294
27. E.M. Hawes, A.M. Deal, D. Funk-Adcock, R. Gosselin, C. Jeanneret, and A.M. Cook Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamics study based on peak and trough levels J Thromb Haemost 11 2013 1493 1502
28. E.M. Schmitz, K. Boonen, D.J. van den Heuvel, J.L. van Dongen, M.W. Schellings, and J.M. Emmen Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants J Thromb Haemost 12 2014 1636 1646
29. D.M. Adcock Funk Coagulation assays and anticoagulant monitoring Hematology. American Society of Hematology Education Program Book 2012 460 465
30. R.C. Gosselin, S.J. Francart, E.M. Hawes, and D.M. Adcock Funk Comparison of anti-Xa and DRVVT assays in quantifying drug levels in patients on therapeutic dises of rivaroxaban Arch Pathol Lab Med 138 2014 1680 1684
31. R.C. Gosselin, S.J. Francart, E.M. Hawes, S.M. Moll, W.E. Dager, and D.M. Adcock Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: Can this test be used to quantify drug level? Ann Phamacother 2015 10.1177/1060028015578451
32. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J Thromb Haemost 11 2013 756 760
33. T. Baglin, D. Keeling, and S. Kitchen Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology Br J Haematol 159 2012 427 429
34. R. Gosselin, D. Adcock, E.M. Hawes, S.J. Francart, S. Moll, and R.P. Grant Evaluating the use of commercial drug specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban Thromb Haemost 113 2015 77 84
35. R.A. Dieri, and H.C. Hemker Monitoring new oral antithrombotics: what we should know before we can decide J Thromb Haemost 8 2010 2833 2835
36. M. Cushman, W. Lim, and N.A. Zakai Clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults 2011 The American Society of Hematology [ http://222.hemataology.org/Practice/Guidelines/2934.aspx. Published 2011. Accessed 11Feb2015]
37. W.E. Dager, R.C. Gosselin, S. Kitchen, and D. Dwyre Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study Ann Pharmacother 46 2012 1627 1636
38. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, and G. Palareti Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost 106 2011 868 876
39. J. Stangier, and M. Feuring Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran Blood Coagul Fibrinolysis 23 2012 138 143
40. R. Gosselin, E. Hawes, S. Moll, and D. Adcock Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses. A prospective study based on peak and trough levels Am J Clin Pathol 141 2014 262 267
41. D.M. Adcock, R. Gosselin, S. Kitchen, and D.M. Dwyre The effect of dabigatran on select specialty coagulation assays Am J Clin Pathol 139 2013 102 109
42. H. Mani Interpretation of coagulation test results under direct oral anticoagulants Int J Lab Hematol 36 2014 262 368
43. C. Eby Novel anticoagulants and laboratory testing Int J Lab Hematol 2013 262 268
44. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, L.L. Flem, and C. Guinet Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial Clin Appl Thromb Hemost 18 2012 150 158
45. A. Hillarp, K.M. Gustafsson, L. Faxälv, K. Strandberg, F. Baghaei, and I. Fagerberg Blixter Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays J Thromb Haemost 12 2014 1545 1553
46. B.J. Dale, J.S. Ginsberg, M. Johnston, J. Hirsh, J.I. Weitz, and J.W. Eikelboom Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents J Thromb Haemost 12 2014 1810 1815
47. S. Francart, E.M. Hawes, A. Deal, D. Adcock, R. Gosselin, and C. Jeanneret Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels Thromb Haemost 111 2014 1133 1140
48. A. Hillarp, F. Baghaei, Fagerberb, and I. Blixter Effects of oral direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays J Thromb Haemost 9 2011 133 139
49. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
50. Y. Morishima, and C. Kamisato Laboratory measurements of the oral direct factor Xa inhibitor edoxaban Am J Clin Pathol 743 2015 241 247
51. R.C. Becker, H. Yang, Y. Barrett, P. Mohan, J. Wang, and L. Wallentin Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor J Thromb Thrombolysis 32 2011 183 187
52. G.J. Hankey, B. Norrving, W. Hacke, and T. Steiner Management of acute stroke patients taking novel oral anticoagulants Int J Stroke 9 2014 627 632